NKGN · As filed with the SEC
NKGen Biotech balance sheet, by fiscal year
The statement as NKGen Biotech presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD thousands
| USD thousands | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 106 | 26 | 635.16 | 1,722.51 |
| Prepaid expenses | — | — | 242,752 | 812,724 |
| Accounts receivable | — | 0 | — | — |
| Restricted cash | 129 | 250 | — | — |
| Prepaid expenses and other current assets | 2,224 | 1,654 | — | — |
| Total current assets | 2,459 | 1,930 | 877.91 | 2,535.23 |
| Investments held in Trust Account | — | — | 173,488,201 | 171,656,153 |
| Property and equipment, net | 13,297 | 14,459 | — | — |
| Operating lease right-of-use assets, net | 379 | 0 | — | — |
| Capitalized software, net | 96 | 92 | — | — |
| Total assets | 16,231 | 16,481 | 174,366.11 | 174,191.38 |
| Liabilities and Stockholders’ Deficit | ||||
| Current liabilities: | ||||
| Accounts payable | — | — | 177,157 | 51,807 |
| Accrued expenses | — | — | 2,444,352 | 1,656,137 |
| Franchise tax payable | — | — | 42,705 | 185,205 |
| Income tax payable | — | — | 181,374 | — |
| Accounts payable and accrued expenses (including related party amounts of $492 and $688 as of December 31, 2024 and 2023, respectively) | 15,668 | 13,395 | — | — |
| Forward purchase derivative liability | 148 | 15,804 | — | — |
| Convertible debt | — | 0 | — | — |
| Convertible promissory notes, due to related parties | — | 0 | — | — |
| Promissory Notes | 32,410 | — | — | — |
| Convertible Bridge Loans | 244 | — | — | — |
| Revolving line of credit | 5,257 | 4,991 | — | — |
| Related party loans | — | 5,000 | — | — |
| Related party loans | 4,000 | — | — | — |
| Operating lease liability, current | 154 | 0 | — | — |
| Other current liabilities (including related party amounts of zero and $202 as of December 31, 2024 and 2023, respectively) | 90 | 262 | — | — |
| Total current liabilities | 57,971 | 39,452 | 2,845.59 | 1,893.15 |
| Derivative warrant liability | — | — | 424,940 | 5,571,410 |
| Deferred underwriting commissions in connection with the initial public offering | — | — | 2,102,284 | 6,006,525 |
| Deferred tax liability | 8 | 33 | — | — |
| Derivative warrant liabilities | 17,073 | 25,759 | — | — |
| Operating lease liability, non-current | 246 | — | — | — |
| Senior convertible promissory notes, noncurrent, due to related parties | 10,841 | 9,930 | — | — |
| Total liabilities | 86,139 | 75,174 | 5,372.81 | 13,471.08 |
| Class A common stock subject to possible redemption | — | — | 173,164,122 | 171,615,000 |
| Stockholders’ deficit: | ||||
| Common stock, $0.0001 par value; 500,000,000 authorized shares as of December 31, 2024 and 2023; 44,238,754 and 21,888,976 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 4 | 2 | — | 0.43 |
| Common stock not subject to possible redemption | — | — | 429 | — |
| Additional paid-in capital | 136,686 | 121,727 | 0 | — |
| Subscription receivable | (182) | (17,792) | — | — |
| Receivable from shareholder | 0 | (500) | — | — |
| Accumulated deficit | (206,416) | (162,130) | (4,171.26) | (10,895.13) |
| Total stockholders’ deficit | (69,908) | (58,693) | (4,170.83) | (10,894.70) |
| Total liabilities and stockholders’ deficit | 16,231 | 16,481 | 174,366.11 | 174,191.38 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.